易瑞沙治疗晚期肺腺癌临床观察

Clinical observation of iressa in the treatment of advanced adenocarcinoma of lung

目的观察易瑞沙治疗晚期肺腺癌的疗效及毒副反应。方法对35例Ⅳ期经化疗失败的肺腺癌患者应用易瑞沙,每次250 mg,每天1次,口服,至病情进展。结果35例患者中,CR 2例,PR 12例,有效率43.6%;不吸烟者CR 2例,吸烟者CR 0例,PR 2例,差异有显著性(P=0.04);男性CR 0例,PR1例,女性CR 2例,PR 11例,差异有显著性(P=0.038)。24例出现皮肤改变,7例有轻度腹泻,无需停药。1例CR和2例PR患者在服药11个月和12个月后出现复发和新病灶。结论易瑞沙能有效缓解晚期化疗失败的肺腺癌不吸烟女性患者的病情,毒副反应可以耐受。但长期服用易瑞沙可能出现耐药。

Objective To observe the effects of iressa in the treatment of advanced lung adenocarcinoma and its toxicity reaction.Methods Iressa was administered to 35 phase II patients with lung adenocarcinoma who failed in the chemotherapy,each with 250mg,oral,once a day,until progress of the disease.Results Of all the 35 cases,there were 2 cases of CR,12 cases of PR.The efficiency rate was 43.6%.Furthermore,2 cases of CR and 10 cases of PR occurred in non-smokers while no case of CR and 2 cases of PR in smokers.The difference was statistically significant（P=0.04）.There was no case of CR and 1 case of PR in the males and 2 cases of CR and 11 cases of PR in the females,which also indicated remarkable difference（P=0.038）.24 cases developed skin changes and another 7 cases mild diarrhea,with no drug withdrawal followed.Recurrence and new lesions occurred in 1 case of CR and 2 cases of PR 11 months and 12 months respectively after drug administration.Conclusion Iressa can effectively relieve the condition of the non-smoking female patients with advanced lung adenocarcinoma who failed in chemotherapy.Its toxicity is tolerable.But long-term use may lead to drug resistance.